<DOC>
	<DOCNO>NCT01511432</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability , safety , tolerability 3 new formulation telaprevir relative Incivek 375-mg tablet .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Three New Formulations Telaprevir Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Healthy subject ( male female nonchildbearing potential ) age 18 55 year Nonchildbearing potential female subject Male subject female partner must agree use least 2 method contraception Subjects body mass index ( BMI ) 18 30 kg/m2 weigh &gt; 50 kg Screening Visit . Subjects positive test result hepatitis B , hepatitis C , HIV Subjects significant history illness , deem important investigator condition possibly affect drug absorption Subjects positive urine screen drug abuse Subjects history regular alcohol consumption Subjects treat investigational drug within 30 day For Part A : Subjects 12lead ECG QTcF &gt; 450 msec ( male ) QTcF &gt; 470 msec ( female ) Screening Visit Subjects use prescription and/or nonprescription medication vitamins and/or dietary supplement Subjects make blood donation approximately 1 pint ( 500 mL ) within 56 day prior first dose study drug Subjects female partner pregnant , nursing , plan become pregnant study within 90 day last dose study drug Subjects hormone replacement therapy ( HRT ) must discontinue therapy 28 day prior first dose study drug Subjects habit use tobacco nicotine containing product within 6 month Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>telaprevir formulation</keyword>
</DOC>